

Note: [01 Mar 2017] – The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative.

FORM 13-501F1
CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS –
PARTICIPATION FEE

MANAGEMENT CERTIFICATION

<p>MARK UPSDELL I, _____, an officer of the reporting issuer noted below have examined this Form 13-501F1 (the Form) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.</p>	
"Mark Upsdell" _____ Name: MARK UPSDELL Title: CEO	Jan 27, 2023 _____ Date:

Reporting Issuer Name: _____ Rapid Dose Therapeutics Corp _____

End date of previous financial year: _____ Feb 28 2022 _____

Type of Reporting Issuer: **Class 1 reporting issuer** **Class 3B reporting issuer**

Highest Trading Marketplace: _____ Cdn Securities Exchange _____

Market value of listed or quoted equity securities:

Equity Symbol _____ DOSE _____

1st Specified Trading Period (dd/mm/yy) _____ 01/03/2021 _____ to _____ 31/05/2021 _____

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ _____ 0.21
(i)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period 99,417,923

(ii)

Market value of class or series (i) x (ii) \$ 20,877,764

(A)

2nd Specified Trading Period (dd/mm/yy) 01/06/2021 to 31,08/2021
_____ to _____

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace 0.60
\$ _____
(iii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period 101,438,923

(iv)

Market value of class or series (iii) x (iv) \$ 60863354

(B)

3rd Specified Trading Period (dd/mm/yy) 01/09/2021 to 31/11/2021
_____ to _____

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace 0.55
\$ _____
(v)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period 102,493,610

(vi)

Market value of class or series (v) x (vi) \$ 56,371,486

(C)

4th Specified Trading Period (dd/mm/yy)

01/12/2021 to 28/02/2022

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ _____ .255
(vii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

_____ 13,068,110
(viii)

Market value of class or series

(vii) x (viii) \$ _____ 26,282,368
(D)

5th Specified Trading Period (dd/mm/yy)

_____ to _____

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ _____
(ix)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

_____ (x)

Market value of class or series

(ix) x (x) \$ _____
(E)

Average Market Value of Class or Series (Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))

\$ _____
(1)

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

Fair value of outstanding debt securities:

(Provide details of how value was determined) \$ 759,000
(2)

Capitalization for the previous financial year (1) + (2) \$ 27,041,368

Participation Fee \$ 1200.00

Late Fee, if applicable \$ 240.00

Total Fee Payable \$ 1440.00
(Participation Fee plus Late Fee)